**PRISMA Checklist**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/Topic** | **#** | **Checklist item**  | **Reported on page #** |
| **TITLE** |  |
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
| **ABSTRACT** |  |
| Structured summary | 2 | Provide a structured summary including as applicable: background; objectives; data sources; study elegibility criteria, partecipants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 3 |
| **INTRODUCTION** |  |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known | 4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to partecipants, interventions, comparisons, outcomes, and study design. | 4 |
| **METHODS** |   |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed, and, if available, provide registration including registration number. | Not applicable |
| Elegibility criteria | 6 | Specify study characteristics and report characteristics used as criteria for eligibility giving a rationale. | 5 |
| Information sources | 7 | Describe all information source in the search and date last searched. | 5 |
| Search | 8 | Present full electronic search strategy for at least one database, inluding any limits used, such that it could be repeated. | 5 |
| Study selection | 9 | State the process for selecting studies. | 5 |
| Data collection process | 10 | Describe method of data extraction from report and any processes for obtaining and confirming data from investigators. | 5 |
| Data items | 11 | List and define all variables for which data were sought and any assumptions and semplifications made. | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies, and how this information is to be used in any data synthesis. | 5 |
| Summary measures | 13 | State the principal summary measures. | 5 |
| Synthesis of results | 14 | Describe methods of handling data and combining results of studies, if done, including measures of consistency (e.g. I2) for each meta-analysis | 5-6 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  | 6-7 |
| Additional analysis | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were prespecified.  | 6 |
| **RESULTS** |  |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  | Figure 1 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  | Supplemental contents |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment.  | We evaluated the quality of studies using REMARK checklist |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  | Supplemental contents |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. |  7-10 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15).  | 10 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression. | 7-10 |
| **DISCUSSION** |  |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  | 10 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  | 13 |
| Conclusions  | 26 | Provide general interpretation of the results in the context of other evidence, and implications for future research.  | 13-14 |
| **FUNDING** |  |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  | 14 |